InspireMD Q4 2024 Earnings Report
Key Takeaways
InspireMD reported Q4 2024 revenue of $1.95 million, up 10.7% year-over-year, driven by expansion into new and existing markets. However, gross profit declined to $469,000 due to higher material and labor costs. Operating expenses surged by 55.8% to $9.84 million, mainly due to increased personnel and regulatory expenses in preparation for the anticipated U.S. launch of CGuard Prime. The company posted a net loss of $9.17 million, or $0.19 per share.
Q4 revenue increased 10.7% to $1.95 million.
Gross profit declined 7.1% to $469,000 due to higher costs.
Operating expenses rose 55.8% to $9.84 million, driven by expansion efforts.
Net loss widened to $9.17 million, or $0.19 per share.
InspireMD
InspireMD
InspireMD Revenue by Segment
Forward Guidance
InspireMD is preparing for the potential U.S. commercial launch of CGuard Prime in the first half of 2025, pending FDA approval. The company expects continued investments in regulatory and commercial activities to support its growth strategy.
Positive Outlook
- Anticipated FDA approval for CGuard Prime in the first half of 2025.
- Strong growth in CGuard EPS sales in new and existing markets.
- Increased engagement with regulatory bodies to support expansion.
- Expansion of personnel and sales force in the U.S.
- Potential for market expansion into the transcarotid revascularization (TCAR) segment.
Challenges Ahead
- Higher operational costs leading to increased net losses.
- Continued investments in commercialization efforts before revenue realization.
- Regulatory risks associated with FDA approval process.
- Potential supply chain and cost challenges due to increased demand.
- Market competition from established players in the carotid stent segment.